Coherus Looks To Raise $200m Amid Coronavirus Impact

Comes As Firm Warns Of Possible COVID-19 Adversity

Coherus BioSciences plans to dip into the financing market once again in order to fuel its operations, which include several biosimilar candidates in late-stage clinical development. However, at the same time, the firm has acknowledged the damage the accelerating COVID-19 crisis could have on operations, if only for a short while.

Dollars
Coherus will use some of the proceeds for pipeline acquisitions or licenses • Source: Shutterstock

Coherus BioSciences has announced plans for a round of financing worth an initial $200m by issuing convertible senior notes, to be used in part for “for opportunistic pipeline acquisitions or licenses, working capital, and other general corporate purposes, which may include other debt repayment in the future.”

The biosimilars player underlined it had not “entered into any agreements or commitments with respect to any material acquisitions or...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business